Skip to main content

Advertisement

SpringerLink
Log in

Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

We performed repetitive molecular staging using, nested rt-PCR for PSA and PSM at the peripheral blood (PB) and bone marrow (BM) of patients with prostate cancer (Pr.Ca) and benign prostate hyperplasia (BPH) after transrectal ultrasonography-guided biopsy (TRUS-B; 6–9 biopsies/patient), Pr.Ca patients after radical prostatectomy (RP), and Pr.Ca patients with diffuse bony metastases. All BPH patients (N = 20) tested negative at BM. Of the 2 who tested positive at PB 2 weeks after TRUS-B tested negative 8 weeks after TRUS-B. Of the 17 Pr.Ca, 7 (41.2%) tested positive at PB for PSA and PSM 2 weeks after TRUS-B while only 4 (23.5%) of them tested positive at repetitive analysis 8 weeks after TRUS-B. Two (11.8%) of the 17 Pr.Ca patients had positive analysis at BM for PSA and PSM 2 and 8 weeks after TRUS-B. Of 12 Pr.Ca patients with negative pre-operative molecular staging, 7 (58.3%) tested positive at PB for PSA and PSM 2 months post-RP but only 3 (25%) of them re-tested positive 12 months post-RP. Of these 12 Pr.Ca, 4 (33.3%) tested positive at BM for PSA and PSM 2 months post-RP while none re-tested positive 12 months post-RP. All Pr.Ca (N = 20) with diffuse bony lesions tested positive at BM. At PB, 6 of them (30%) tested negative for both PSA and PSM. Our data suggest that nested rt-PCR for PSA and PSM at PB is affected by TRUS-B and RP, while such analysis at BM concerted diffuse bony disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wood PD Jr, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol 1997; 12: 3451–57.

    Google Scholar 

  2. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In Walsh PC, Retik AB, Stamey TA et al. (eds): Campbells Urology. Philadelphia, Saunders, 1992, 1159–221.

    Google Scholar 

  3. Rifkin MD, Zertouni EA, Gatsonis CA et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. N Engl J Med 1990; 323: 621-6.

    Article  PubMed  CAS  Google Scholar 

  4. Lerner SP, Seale-Hawkins C, Carlton CE Jr et al. The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 1991; 146: 1040–45.

    PubMed  CAS  Google Scholar 

  5. Pontes JE, Wajsman Z, Huben RP et al. Prognostic factors in localized prostate carcinoma. J Urol 1985; 134: 1137–9.

    PubMed  CAS  Google Scholar 

  6. Ennis RD, Peschel RE. Radiation therapy for prostate cancer. Cancer 1993; 72: 2644–50.

    Article  PubMed  CAS  Google Scholar 

  7. Gomella LG, Raj GV, Moreno JG. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol 1997; 158: 326–37.

    Article  PubMed  CAS  Google Scholar 

  8. Deguchi T, Yang M, Ito S, Nishino Y et al. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer 1997; 75: 634–8.

    PubMed  CAS  Google Scholar 

  9. Wood DP jr, Banks ER, Humphrey S et al. Identification of bone metastases in patients with prostate cancer. Cancer 1994; 74: 2533–40

    Article  PubMed  Google Scholar 

  10. Cama C, Olsson CA, Raffo AJ et al. Molecular staging of prostate cancer. II. a comparison of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 1995; 153: 1373–8.

    Article  PubMed  CAS  Google Scholar 

  11. Katz AE, de Vries GM, Begg MD et al. Enhanced reverse transcriptase-polymerase chain reaction as an indicator of true pathologic stage in patients with prostate cancer. Cancer 1995; 75: 1642–8.

    Article  PubMed  CAS  Google Scholar 

  12. Loric S, Dumas F, Eschwege P et al. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse trancriptase polymerase chain reaction assay based on prostate specific membrane antigen. Clin Chem 1995;41: 1698–1704.

    PubMed  CAS  Google Scholar 

  13. Melchior SW, Corey E, Ellis WJ et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997; 3: 249–56.

    PubMed  CAS  Google Scholar 

  14. Grasso YZ, Gupta MK, Levin HS et al. Combined nested rt-PCR assay for prostate specific antigen and prostate specific membrane antigen in prostate cancer patients: Correlation with pathologic stage. Cancer Res 1998; 58: 1456–9.

    PubMed  CAS  Google Scholar 

  15. Israeli RS, Miller WH, Su SL et al. Sensitive reverse transcriptase polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994; 54: 6306–10.

    PubMed  CAS  Google Scholar 

  16. Olsson CA, de Vries MC, Benson MC et al. The use of rt-PCR for prostate specific antigen assay to predict surgical failures before radical prostatectomy: Molecular staging of the prostate cancer. Br J Urol 1996; 77: 411–7.

    PubMed  CAS  Google Scholar 

  17. Su SL, Heston DW, Perotti M et al. Evaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostate-specific membrane reverse transcriptase polymerase chain reaction. Urology 1997; 49: 95–101.

    Article  PubMed  CAS  Google Scholar 

  18. Eschwege P, Dumas F, Blancet P et al. Heamotogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 1995; 346: 1528–30.

    Article  PubMed  CAS  Google Scholar 

  19. Koutsilieris M, Dimopoulos MA, Doillon C et al. The molecular consept of prostate cancer. Cancer J 1996; 9: 89–94.

    Google Scholar 

  20. Kibel AS, Krithivas K, Shamel B et al. Constitutive expression of high levels of prostate specific antigen in the absence of prostate carcinoma. Urology 1996; 48: 741–6.

    Article  PubMed  CAS  Google Scholar 

  21. Lintula S, Stenman U-H. The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol 1997; 157: 1969–72.

    Article  PubMed  CAS  Google Scholar 

  22. Gala J-L, Heusterspreute M, Loric S et al. Expression of prostatespecific antigen and prostate specific membrane antigen transcripts in peripheral blood cells: Implications for the detection of hematogenous prostate cells and standardization. Clin Chem 1998; 44: 472–81.

    PubMed  CAS  Google Scholar 

  23. Reyes-Moreno C, Sourla A, Choki I, Koutsilieris M. Osteoblastderived survival factors protect PC-3 human prostate cancer cells from adriamycin-apoptosis. Urology 1998; 52: 341–7.

    Article  PubMed  CAS  Google Scholar 

  24. Koutsilieris M, Reyes-Moreno C, Choki J et al. Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors. Mol Med 1999; 5: 86–97.

    PubMed  CAS  Google Scholar 

  25. Koutsilieris M, Tzanela M, Dimopoulos T. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer. Prostate 1999; 38: 313–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Experimental Physiology, Medical School, University of Athens, Athens, Greece

    Michael Koutsilieris & Panayiotis Lembessis

  2. Molecular Endocrinology Laboratory, Centre Hospitalier, Universite de Quebec (CHUQ), Laval University, Ste. Foy, Quebec, Canada

    Van Luu-The

  3. Endo/OncoResearch Diagnostic and Therapeutic Center, Mavilis Square, Athens, Greece

    Antigone Sourla

Authors
  1. Michael Koutsilieris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Panayiotis Lembessis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Van Luu-The
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antigone Sourla
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koutsilieris, M., Lembessis, P., Van Luu-The et al. Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. Clin Exp Metastasis 17, 823–830 (1999). https://doi.org/10.1023/A:1006783330996

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006783330996

Search

Navigation